new york mets, Jose Iglesias and Nick Madrigal
Mets still view Jose Iglesias as 'not a fit' after Nick Madrigal's injury, source says
They still view Iglesias as “not a fit” for their roster, according to a person familiar with the Mets’ thinking. That leaves them with several in-house options, none ideal, to replace Madrigal as the backup infielder.
Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.
Shares of Madrigal Pharmaceuticals ( MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...
Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...
Nick Madrigal is fighting for a roster spot with the Mets, and it’s unclear how much time he’ll miss after the injury to his ...
Madrigal Pharmaceuticals (MDGL) reported Q4 results and provided a 2-year update from the open-label metabolic dysfunction-associated ...
The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...
The Mets’ bench competition experienced some early upheaval on Sunday, when infielder Nick Madrigal dislocated his left ...
Reports Q4 revenue $103.3M, consensus $97.81M. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Looking back on 2024, I’m incredibly ...
WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Wednesday reported a loss of $59.4 million in its fourth quarter. The West Conshohocken, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback